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ABSTRACT  
We conducted genome-wide association studies of three phenotypes: subjective well-being 
(N = 298,420), depressive symptoms (N = 161,460), and neuroticism (N = 170,910). We 
identified three variants associated with subjective well-being, two with depressive 
symptoms, and eleven with neuroticism, including two inversion polymorphisms. The two 
depressive symptoms loci replicate in an independent depression sample. Joint analyses 
that exploit the high genetic correlations between the phenotypes (|࣋ෝ| ൎ ૙. ૡ) strengthen the 
overall credibility of the findings, and allow us to identify additional variants. Across our 
phenotypes, loci regulating expression in central nervous system and adrenal/pancreas 
tissues are strongly enriched for association. 
INTRODUCTION  
Subjective well-being—as measured by survey questions on life satisfaction, positive affect, or 
happiness—is a major topic of research within psychology, economics, and epidemiology. Twin 
studies have found that subjective well-being is genetically correlated with depression 
(characterized by negative affect, anxiety, low energy, bodily aches and pains, pessimism, and 
other symptoms) and neuroticism (a personality trait characterized by easily experiencing negative 
emotions such as anxiety and fear)1–3. Depression and neuroticism have received much more 
attention than subjective well-being in genetic-association studies, but the discovery of associated 
genetic variants with either of them has proven elusive4,5. 
In this paper, we report a series of separate and joint analyses of subjective well-being, depressive 
symptoms, and neuroticism. Our primary analysis is a genome-wide association study (GWAS) of 
subjective well-being based on data from 59 cohorts (N = 298,420). This GWAS identifies three 
loci associated with subjective well-being at genome-wide significance (p < 5×10-8). We 
supplement this primary analysis with auxiliary GWAS meta-analyses of depressive symptoms (N 
= 180,866) and neuroticism (N = 170,910), performed by combining publicly available summary 
statistics from published studies with new genome-wide analyses of additional data. In these 
auxiliary analyses we identify two loci associated with depressive symptoms and eleven with 
neuroticism, including two inversion polymorphisms. In depression data from an independent 
sample (N = 368,890), both depressive symptoms associations replicate (p = 0.004 and p = 
0.015). 
In our two joint analyses, we exploit the high genetic correlation between subjective well-being, 
depressive symptoms, and neuroticism (i) to evaluate the credibility of the 16 genome-wide 
significant associations across the three phenotypes, and (ii) to identify novel associations 
(beyond those identified by the GWAS). For (i), we investigate whether our three subjective well-
being-associated SNPs “quasi-replicate” by testing them for association with depressive 
symptoms and neuroticism. We similarly examine the quasi-replication record of the depressive 
symptoms and neuroticism loci by testing them for association with subjective well-being. We find 
that the quasi-replication record closely matches what would be expected given our statistical 
power if none of the genome-wide significant associations were chance findings. These results 
strengthen the credibility of (most of) the original associations. For (ii), we use a “proxy phenotype” 
approach6: we treat the set of loci associated with subjective well-being at p < 10-4 as candidates, 
and we test them for association with depressive symptoms and neuroticism. At the Bonferroni-
adjusted 0.05 significance threshold, we identify two loci associated with both depressive 
symptoms and neuroticism and another two associated with neuroticism. 
In designing our study, we faced a tradeoff between analyzing a smaller sample with a 
homogeneous phenotype measure versus attaining a larger sample by jointly analyzing data from 
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multiple cohorts with heterogeneous measures. For example, in our analysis of subjective well-
being, we included measures of both life satisfaction and positive affect, even though these 
constructs are conceptually distinct7. In Supplementary Note and Supplementary Figure 1, we 
present a theoretical framework for evaluating the costs and benefits of pooling heterogeneous 
measures. In our context, given the high genetic correlation across measures, the framework 
predicts that pooling increases statistical power to detect variants. This prediction is supported by 
our results. 
RESULTS 
GWAS of subjective well-being 
Following a pre-specified analysis plan, we conducted a sample-size-weighted meta-analysis (N = 
298,420) of cohort-level GWAS summary statistics. The phenotype measure was life satisfaction, 
positive affect, or (in some cohorts) a measure combining life satisfaction and positive affect. We 
confirmed previous findings9 of high pairwise genetic correlation between life satisfaction and 
positive affect using bivariate LD Score regression10 (ߩො = 0.981 (SE = 0.065); Supplementary 
Table 1). Details on the 59 participating cohorts, their phenotype measures, genotyping, quality-
control filters, and association models are provided in Online Methods, Supplementary Note, and 
Supplementary Tables 2-6. 
As expected under polygenicity11, we observe inflation of the median test statistic (λGC = 1.206). 
The estimated intercept from LD Score regression (1.012) suggests that nearly all of the inflation is 
due to polygenic signal rather than bias. We also performed family-based analyses that similarly 
suggest minimal confounding due to population stratification (Online Methods). Using a clumping 
procedure (Supplementary Note), we identified three approximately independent SNPs reaching 
genome-wide significance (“lead SNPs”). These three lead SNPs are indicated in the Manhattan 
plot (Figure 1a) and listed in Table 1. The SNPs have estimated effects in the range 0.015 to 
0.018 standard deviations (SDs) per allele (each R2	ൎ	0.01%). 
We also conducted separate meta-analyses of the components of our subjective well-being 
measure, life satisfaction (N = 166,205) and positive affect (N = 180,281) (Online Methods). 
Consistent with our theoretical conclusion that pooling heterogeneous measures increased power 
in our context, the life satisfaction and positive affect analyses yielded fewer signals across a 
range of p-value thresholds than our meta-analysis of subjective well-being (Supplementary 
Table 7). 
GWAS of depressive symptoms and neuroticism 
We conducted auxiliary GWAS of depressive symptoms and neuroticism (see Online Methods, 
Supplementary Note, and Supplementary Tables 8-12 for details on cohorts, phenotype 
measures, genotyping, association models, and quality-control filters). For depressive symptoms 
(N = 180,866), we meta-analyzed publicly available results from a study performed by the 
Psychiatric Genomics Consortium (PGC)12 together with new results from analyses of the initial 
release of the UK Biobank data (UKB)13 and the Resource for Genetic Epidemiology Research on 
Aging (GERA) Cohort14. In UKB (N = 105,739), we constructed a continuous phenotype measure 
by combining responses to two questions, which ask about the frequency in the past two weeks 
with which the respondent experienced feelings of unenthusiasm/disinterest and 
depression/hopelessness. The other cohorts had ascertained case-control data on major 
depressive disorder (GERA: Ncases = 7,231, Ncontrols = 49,316; PGC: Ncases = 9,240, Ncontrols = 
9,519). 
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For neuroticism (N = 170,910), we pooled summary statistics from a published study by the 
Genetics of Personality Consortium (GPC)4 with results from a new analysis of UKB data. The 
GPC (N = 63,661) harmonized different neuroticism batteries. In UKB (N = 107,245), our measure 
was the respondent’s score on a 12-item version of the Eysenck Personality Inventory Neuroticism 
scale15. 
In both the depressive symptoms and neuroticism GWAS, the heterogeneous phenotypic 
measures are highly genetically correlated (Supplementary Table 1). As in our subjective well-
being analyses, there is substantial inflation of the median test statistics (λGC = 1.168 for 
depressive symptoms, λGC = 1.317 for neuroticism), but the estimated LD Score intercepts (1.008 
and 0.998, respectively) suggest that bias accounts for little or none of the inflation. 
For depressive symptoms, we identified two lead SNPs, indicated in the Manhattan plot (Fig. 1b). 
For neuroticism, our meta-analysis yielded 16 loci that are independent according to our locus 
definition (Fig. 1c). However, 6 of these reside within a well-known inversion polymorphism16 on 
chromosome 8. We established that all genome-wide significant signals in the inversion region are 
attributable to the inversion, and we confirmed that the inversion is associated with neuroticism in 
both of our neuroticism datasets, the GPC and the UKB (Online Methods and Supplementary 
Note). In our list of lead SNPs (Table 1), we only retain the most strongly associated SNP from 
these 6 loci to tag the chromosome 8 inversion. 
Another lead SNP associated with neuroticism, rs193236081, is located within a well-known 
inversion polymorphism on chromosome 17. We established that this association is attributable to 
the inversion polymorphism (Online Methods and Supplementary Note). Because this inversion 
yields only one significant locus and is genetically complex17, we hereafter simply use its lead SNP 
as its proxy. Our neuroticism GWAS therefore identified 11 lead SNPs, two of which tag inversion 
polymorphisms. A concurrent neuroticism GWAS using a subset of our sample reports similar 
findings18. 
As shown in Table 1, the estimated effects of all lead SNPs associated with depressive symptoms 
and neuroticism are in the range 0.020 to 0.031 SDs per allele (R2 ൎ 0.02% to 0.04%). In the UKB 
cohort we estimated the effect of an additional allele of the chromosome 8 inversion polymorphism 
itself on neuroticism to be 0.035 SDs (Supplementary Table 13). The inversion explains 0.06% of 
the variance in neuroticism (roughly the same as the total variance explained jointly by the 6 SNPs 
in the inversion region). 
Genetic overlap across subjective well-being, depressive symptoms, and neuroticism 
Figure 2a shows that the three pairwise genetic correlations between our phenotypes, estimated 
using bivariate LD Score regression10, are substantial: -0.81 (SE = 0.046) between subjective well-
being and depressive symptoms, -0.75 (SE = 0.034) between subjective well-being and 
neuroticism, and 0.75 (SE = 0.027) between depressive symptoms and neuroticism. Using height 
as a negative control, we also examined pairwise genetic correlations between each of our 
phenotypes and height and, as expected, found all three to be modest, e.g., 0.07 with subjective 
well-being (Supplementary Table 1). The high genetic correlations between subjective well-
being, depressive symptoms, and neuroticism may suggest that the genetic influences on these 
phenotypes are predominantly related to processes common across the phenotypes, such as 
mood, rather than being phenotype-specific. 
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Quasi-replication and Bayesian credibility analyses 
We assessed the credibility of our findings using a standard Bayesian framework19,20 in which a 
positive fraction of SNPs have null effects and a positive fraction have non-null effects (Online 
Methods). For each phenotype, the non-null effect sizes are assumed to be drawn from a normal 
distribution whose variance is estimated from the GWAS summary statistics. As a first analysis, for 
each lead SNP’s association with its phenotype, we calculated the posterior probability of null 
association after having observed the GWAS results. We found that, for any assumption about the 
fraction of non-null SNPs in the range 1% to 99%, the probability of true association always 
exceeds 95% for all 16 loci (and always exceeds 98% for 14 of them). 
To further probe the credibility of the findings, we performed “quasi-replication” exercises (Online 
Methods) in which we tested the subjective well-being lead-SNPs for association with depressive 
symptoms and neuroticism. We similarly tested the depressive symptoms lead-SNPs and the 
neuroticism lead-SNPs for association with subjective well-being. Below, we refer to the 
phenotype for which the lead SNP was identified as the first-stage phenotype and the phenotype 
used for the quasi-replication as the second-stage phenotype. To avoid sample overlap, for each 
quasi-replication analysis we omitted any cohorts that contributed to the GWAS of the first-stage 
phenotype. 
Results of the quasi-replication of the three subjective well-being lead-SNPs are shown in Figure 
3a. For ease of interpretation, the reference allele for each association in the figure is chosen such 
that the predicted sign of the second-stage estimate is positive. We find that two out of the three 
subjective well-being lead-SNPs are significantly associated with depressive symptoms (p = 0.004 
and p = 0.001) in the predicted direction. For neuroticism, where the second-stage sample size (N 
= 68,201) is about half as large, the subjective well-being-increasing allele has the predicted sign 
for all three SNPs, but none reach significance. 
Figures 3b and 3c show the results for the depressive symptoms and neuroticism lead-SNPs, 
respectively. In each panel, the blue crosses depict results from the quasi-replications where 
subjective well-being is the second-stage phenotype. We find that the two depressive symptoms 
lead-SNPs have the predicted sign for subjective well-being, and one is nominally significant (p = 
0.04). Finally, of the eleven neuroticism lead-SNPs, nine have the predicted sign for subjective 
well-being. Four of the eleven are nominally significantly associated with subjective well-being, all 
with the predicted sign. One of the four is the SNP tagging the inversion on chromosome 816. That 
SNP’s association with neuroticism (and likely with subjective well-being) is driven by its 
correlation with the inversion (Supplementary Fig. 2). 
To evaluate what these quasi-replication results imply about the credibility of the 16 GWAS 
associations, we compared the observed quasi-replication record to the quasi-replication record 
expected given our statistical power. We calculated statistical power using our Bayesian 
framework, under the hypothesis that each lead SNP has a non-null effect on both the first- and 
second-stage phenotypes. Our calculations take into account both the imperfect genetic 
correlation between the first- and second-stage phenotypes and inflation of the first-stage 
estimates due to the well-known problem of winner’s curse (Online Methods). Of the 19 quasi-
replication tests, our calculations imply that 16.7 would be expected to yield the anticipated sign 
and 6.9 would be significant at the 5% level. The observed numbers are 16 and 7. Our quasi-
replication results are thus consistent with the hypothesis that none of the 16 genome-wide 
significant associations are chance findings, and in fact strengthen the credibility of our GWAS 
results (Supplementary Table 14). 
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Lookup of depressive symptoms and neuroticism lead-SNPs  
Investigators of an ongoing large-scale GWAS of major depressive disorder (N = 368,890) in the 
23andMe cohort shared association results for the loci identified in our depressive symptoms and 
neuroticism analyses (Online Methods and Supplementary Table 15)21. Because the depression 
sample overlaps with our subjective well-being sample, we did not request a lookup of the 
subjective well-being-associated SNPs.  
In Figures 3b and 3c, the results are depicted as green crosses. For interpretational ease, we 
chose the reference allele so that positive coefficients imply that the estimated effect is in the 
predicted direction. All 13 associations have the predicted sign. Of the 11 neuroticism 
polymorphisms, four are significantly associated with depression at the 5% level. Both of the 
depressive symptoms lead-SNPs replicate (p = 0.004 and p = 0.015), with effect sizes (0.007 and 
-0.007 SDs per allele), close to those predicted by our Bayesian framework (0.008 and -0.006) 
(Supplementary Table 14 and Supplementary Table 15). 
Panel A of Table 1 summarizes the results for the 16 lead SNPs identified across our separate 
GWA analyses of the three phenotypes. The right-most column summarizes the statistical 
significance of the quasi-replication and depression lookup analyses of each SNP. 
Proxy-phenotype analyses 
To identify additional SNPs associated with depressive symptoms, we conducted a two-stage 
“proxy phenotype” analysis (Online Methods). In the first stage, we ran a new GWAS of subjective 
well-being to identify a set of candidate SNPs. Specifically, from each locus exhibiting suggestive 
evidence of association (p < 10-4) with subjective well-being, we retained the SNP with the lowest 
p-value as a candidate. In the second stage, we tested these candidates for association with 
depressive symptoms at the 5% significance threshold, Bonferroni-adjusted for the number of 
candidates. We used an analogous two-stage procedure to identify additional SNPs associated 
with neuroticism. The first-stage subjective well-being sample differs across the two proxy-
phenotype analyses (and from the primary subjective well-being GWAS sample) because we 
assigned cohorts across the first and second stages so as to maximize statistical power for the 
overall procedure. 
For depressive symptoms, there are 163 candidate SNPs. 115 of them (71%) have the predicted 
direction of effect on depressive symptoms, 20 are significantly associated at the 5% significance 
level (19 in the predicted direction), and two remain significant after Bonferroni adjustment. For 
neuroticism, there are 170 candidate SNPs. 129 of them (76%) have the predicted direction of 
effect, all 28 SNPs significant at the 5% level have the predicted sign, and four of these remain 
significant after Bonferroni adjustment (Supplementary Fig. 3 and Supplementary Tables 16 
and 17). Two of the four are the SNPs identified in the proxy-phenotype analysis for depressive 
symptoms.  
Table 1 lists the four SNPs in total identified by the proxy-phenotype analyses. 
Biological analyses 
To shed some light on possible biological mechanisms underlying our findings, we conducted 
several analyses. 
We began by using bivariate LD Score regression10 to quantify the amount of genetic overlap 
between each of our three phenotypes and ten neuropsychiatric and physical health phenotypes. 
Figures 2b and c display the estimates for subjective well-being and the negative of the estimates 
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for depressive symptoms and neuroticism (since subjective well-being is negatively genetically 
correlated with depressive symptoms and neuroticism). Subjective well-being, depressive 
symptoms, and neuroticism have strikingly similar patterns of pairwise genetic correlation with the 
other phenotypes. 
Figure 2b shows the results for the five neuropsychiatric phenotypes we examined: Alzheimer’s 
disease, anxiety disorders, autism spectrum disorder, bipolar disorder, and schizophrenia. For four 
of these phenotypes, genetic correlations with depression (but not neuroticism or subjective well-
being) were reported in Bulik-Sullivan et al.10. For schizophrenia and bipolar disorder, our 
estimated correlations with depressive symptoms, 0.33 and 0.26, are substantially lower than 
Bulik-Sullivan et al.’s point estimates but contained within their 95% confidence intervals. By far 
the largest genetic correlations we estimate are with anxiety disorders: −0.73 with subjective well-
being, 0.88 with depressive symptoms, and 0.86 with neuroticism. Genetic correlations estimated 
from GWAS data have not been previously reported for anxiety disorders. 
Figure 2c shows the results for five physical health phenotypes that are known or believed to be 
risk factors for various adverse health outcomes: body mass index (BMI), ever-smoker status, 
coronary artery disease, fasting glucose, and triglycerides. The estimated genetic correlations are 
all small in magnitude, consistent with earlier work, although the greater precision of our estimates 
allows us to reject null effects in most cases. The signs are generally consistent with those of the 
phenotypic correlations reported in earlier work between our phenotypes and outcomes such as 
obesity22, smoking23,24, and cardiovascular health25. 
Next, to investigate whether our GWAS results are enriched in particular functional categories, we 
applied stratified LD Score regression26 to our meta-analysis results. In our first analysis, we report 
estimates for all 53 functional categories included in the “baseline model”; the results for subjective 
well-being, depressive symptoms, and neuroticism are broadly similar (Supplementary Tables 
18-20) and are in line with what has been found for other phenotypes26. In our second analysis, 
the categories are groupings of SNPs likely to regulate gene expression in cells of a specific 
tissue. The estimates for subjective well-being, depressive symptoms, and neuroticism are shown 
in Figure 4a, alongside height, which is again included as a benchmark27 (see also 
Supplementary Table 21). 
We found significant enrichment of CENTRAL NERVOUS SYSTEM for all three phenotypes and, 
perhaps more surprisingly, enrichment of ADRENAL/PANCREAS for subjective well-being and 
depressive symptoms. The cause of the ADRENAL/PANCREAS enrichment is unclear, but we note 
that the adrenal glands produce several hormones, including cortisol, epinephrine, and 
norepinephrine, known to play important roles in the bodily regulation of mood and stress. It has 
been robustly found that blood serum levels of cortisol in patients afflicted by depression are 
elevated relative to controls28.  
While the above analyses utilize the genome-wide data, we also conducted three analyses (Online 
Methods) restricted to the 16 GWAS and four proxy-phenotype SNPs in Table 1. In brief, we 
ascertained whether each SNP (or a variant in strong linkage disequilibrium (LD) with it) falls into 
any of the following three classes: (i) resides in a locus for which genome-wide significant 
associations with other phenotypes have been reported (Supplementary Table 22), (ii) is 
nonsynonymous (Supplementary Table 23), and (iii) is an eQTL in blood or in one of 14 other 
tissues (although the non-blood analyses are based on smaller samples) (Supplementary Table 
24). Here we highlight a few particularly interesting results. 
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We found that five of the 20 SNPs are in loci in which genome-wide significant associations have 
previously been reported. Two of these five are schizophrenia loci. Interestingly, one of them 
harbors the gene DRD2, which encodes the D2 subtype of the dopamine receptor, a target for 
antipsychotic drugs29 that is also known to play a key role in neural reward pathways30. Motivated 
by these findings, as well as by the modest genetic correlations with schizophrenia reported in 
Figure 2b, we examined whether the SNPs identified in a recent study of schizophrenia31 are 
enriched for association with neuroticism in our non-overlapping UKB sample (N = 107,245). We 
conducted several tests and found strong evidence of such enrichment (Supplementary Note). 
For example, we found that the p-values of the schizophrenia SNPs tend to be much lower than 
the p-values of a randomly selected set of SNPs matched on allele frequency (p = 6.50×10-71). 
Perhaps the most notable pattern that emerges from our biological analyses is that the inversions 
on chromosomes 8 and 17 are implicated consistently across all analyses. The inversion-tagging 
SNP on chromosome 8 is in LD with SNPs that have previously been found to be associated with 
BMI32 and triglycerides33 (Supplementary Table 22). We also conducted eQTL analyses in blood 
for the inversion itself and found that it is a significant cis-eQTL for 7 genes (Supplementary 
Table 24). As shown in Figure 4b, all 7 genes are positioned in close proximity to the inversion 
breakpoints, suggesting that the molecular mechanism underlying the inversion’s effect on 
neuroticism could involve the relocation of regulatory sequences. Two of the genes (MSRA, 
MTMR9) are known to be highly expressed in tissues and cell types that belong to the nervous 
system, and two (BLK, MFHAS1) in the immune system. In the tissue-specific analyses, we found 
that the SNP tagging the inversion is a significant eQTL for two genes, AF131215.9 (in tibial nerve 
and thyroid tissue analyses) and NEIL2 (tibial nerve tissue), both of which are also located near 
the inversion breakpoint. 
The SNP tagging the chromosome 17 inversion is a significant cis-eQTL for five genes in blood 
and is an eQTL in all 14 other tissues (Supplementary Table 24). It alone accounts for 151 out of 
the 169 significant associations identified in the 14 tissue-specific analyses. Additionally, the SNP 
is in near-perfect LD (R2 > 0.97) with 11 missense variants (Supplementary Table 23) in three 
different genes, one of which is MAPT. MAPT, which is also implicated in both the blood and the 
other tissue-specific analyses, encodes a protein important in the stabilization of microtubules in 
neurons. Associations have been previously reported between SNPs in MAPT (all of which are in 
strong LD with our inversion-tagging SNP) and neurodegenerative disorders, including Parkinson’s 
disease34 and progressive supranuclear palsy35, a rare disease whose symptoms include 
depression and apathy. 
DISCUSSION 
The discovery of genetic loci associated with subjective well-being, depression, and neuroticism 
has proven elusive. Our study identified several credible associations for two main reasons. First, 
our analyses had greater statistical power than prior studies because ours were conducted in 
larger samples. Our GWAS findings—three loci associated with subjective well-being, two with 
depressive symptoms, and eleven with neuroticism—support the view that GWAS can 
successfully identify genetic associations with highly polygenic phenotypes in sufficiently large 
samples5,36. A striking finding is that two of our identified associations are with inversion 
polymorphisms. 
Second, our proxy-phenotype analyses further boosted power by exploiting the strong genetic 
overlap between our three phenotypes. These analyses identified two additional loci associated 
with neuroticism and two with both depressive symptoms and neuroticism. Through our quasi-
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replication tests, we also demonstrated how studying genetically overlapping phenotypes in 
concert can provide evidence on the credibility of GWAS findings. Our direct replication of the two 
genome-wide significant associations with depressive symptoms in an independent depression 
sample provides further confirmation of those findings (Fig. 2b and Supplementary Table 15). 
We were able to assemble much larger samples than prior work in part because we combined 
data across heterogeneous phenotype measures. Our results reinforce the conclusions from our 
theoretical analysis that doing so increased our statistical power, but our strategy also has 
drawbacks. One is that mixing different measures may make any discovered associations more 
difficult to interpret. Research studying higher quality measures of the various facets of subjective 
well-being, depressive symptoms, and neuroticism is a critical next step. Our results can help 
facilitate such work because if the variants we identify are used as candidates, studies conducted 
in the smaller samples in which more fine-grained phenotype measures are available can be well 
powered. 
Another limitation of mixing different measures is that doing so may reduce the heritability of the 
resulting phenotype, if the measures are influenced by different genetic factors. Indeed, our 
estimates of SNP-based heritability10 for our three phenotypes are quite low: 0.040 (SE = 0.002) 
for subjective well-being, 0.047 (SE = 0.004) for depressive symptoms, and 0.091 (SE = 0.007) for 
neuroticism. We correspondingly find that polygenic scores constructed from all measured SNPs 
explain a low fraction of variance in independent samples: ~0.9% for subjective well-being, ~0.5% 
for depressive symptoms, and ~0.7% for neuroticism (Online Methods). The low heritabilities imply 
that even when polygenic scores can be estimated using much larger samples than ours, they are 
unlikely to attain enough predictive power to be clinically useful. 
According to our Bayesian calculations, the true explanatory power (corrected for winner’s curse) 
of the SNP with the largest posterior R2 is 0.003% for subjective well-being, 0.002% for depressive 
symptoms, and 0.011% for neuroticism (Supplementary Table 14). These effect sizes imply that 
in order to account for even a moderate share of the heritability, hundreds or (more likely) 
thousands of variants will be required. They also imply that our study’s power to detect variants of 
these effect sizes was not high—for example, our statistical power to detect the lead SNP with 
largest posterior R2 was only ~13%—which in turn means it is likely that there exist many variants 
with effect sizes comparable to our identified SNPs that evaded detection. These estimates 
suggest that many more loci will be found in studies with sample sizes realistically attainable in the 
near future. Consistent with this projection, when we meta-analyze the 54 SNPs reaching p < 10-5 
in our analyses of depressive symptoms together with the 23andMe replication sample for 
depression, the number of genome-wide significant associations rises from 2 to 5 
(Supplementary Table 15).  
 
URLs: 
Genotype-Tissue Expression Portal www.GTExportal.org 
Social Science Genetic Association Consortium (SSGAC) website: 
http://www.thessgac.org/#!data/kuzq8. 
 
ACCESSION CODES: For neuroticism and depressive symptoms, we provide meta-analysis 
results from the combined analyses for all variants. For subjective well-being, meta-analysis 
results for all variants are provided for the full sample excluding 23andMe, for which only up to 
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10,000 SNPs can be reported. Therefore, for the subjective well-being meta-analysis, we provide 
results for 10,000 SNPs. Meta-analysis results can be downloaded from the SSGAC website. 
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Fig. 1. Manhattan plots of GWAS results. (a) Subjective well-being (N = 298,420), (b) Depressive symptoms (N = 180,866), (c) Neuroticism (N 
= 170,911). The x-axis is chromosomal position, and the y-axis is the significance on a −logଵ଴ scale. The upper dashed line marks the threshold 
for genome-wide significance (p = 5×10−8); the lower line marks the threshold for nominal significance (p = 10−5). Each approximately 
independent genome-wide significant association (“lead SNP”) is marked by ×. Each lead SNP is the lowest p-value SNP within the locus, as 
defined by our clumping algorithm (Supplementary Note).  
 
a 
    
b c 
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Fig. 2. Genetic correlations with bars representing 95% confidence intervals. 
The correlations are estimated using bivariate LD Score (LDSC) regression. (a) 
Genetic correlations between subjective well-being, depressive symptoms, and 
neuroticism (“our three phenotypes”), as well as between our three phenotypes and 
height. (b) Genetic correlations between our three phenotypes and selected 
neuropsychiatric phenotypes. (c) Genetic correlations between our three phenotypes 
and selected physical health phenotypes. In (b) and (c), we report the negative of 
the estimated correlation with depressive symptoms and neuroticism (but not 
subjective well-being). 
 
a 
 
b 
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Fig. 3. Quasi-replication and lookup of lead SNPs. In quasi-replication analyses, we examined whether (a) lead SNPs identified in the 
subjective well-being meta-analyses are associated with depressive symptoms or neuroticism, (b) lead SNPs identified in the analyses of 
depressive symptoms are associated with subjective well-being, and (c) lead SNPs identified in the analyses of neuroticism are associated with 
subjective well-being. The quasi-replication sample is always restricted to non-overlapping cohorts. In a separate lookup exercise, we examined 
whether lead SNPs for depressive symptoms and neuroticism are associated with depression in an independent sample of 23andMe customers 
(N = 368,890). The results from this lookup are depicted as green crosses in (b) and (c). Bars represent 95% CIs (not adjusted for multiple 
testing). For interpretational ease, we choose the reference allele so that positive coefficients imply that the estimated effect is in the predicted 
direction. Listed below each lead SNP is the nearest gene. 
 
a 
 
b 
 
  
c 
21 
  
Fig. 4. Results from selected biological analyses. (a) Estimates of the expected 
increase in the phenotypic variance accounted for by a SNP due to the SNP’s being 
in a given category (߬௖), divided by the LD Score heritability of the phenotype (݄ଶ). 
Each estimate of ߬௖ comes from a separate stratified LD Score regression, 
controlling for the 52 functional annotation categories in the “baseline model.” The 
bars represent 95% CIs (not adjusted for multiple testing). To benchmark the 
estimates, we compare them to those obtained from a recent study of height27. (b) 
Inversion polymorphism on chromosome 8 and the 7 genes for which the inversion is 
a significant cis-eQTL at FDR < 0.05. The upper half of the figure shows the 
Manhattan plot for neuroticism for the inversion and surrounding regions. The bottom 
half shows the squared correlation between the SNPs and the principal component 
that captures the inversion. The inlay plots the relationship, for each SNP in the 
inversion region, between the SNP’s significance and its squared correlation with the 
principal component that captures the inversion. 
a 
 
b 
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Table 1. Summary of polymorphisms identified across analyses. EA: effect allele. EAF: 
effect allele frequency. All effect sizes are reported in units of SDs per allele. “Quasi-Repl.”: 
phenotypes for which SNP was found to be nominally associated in quasi-replication analyses 
conducted in independent samples. *significant at the 5%-level, **significant at the 1%-level, 
***significant at the 0.1%-level.  #inversion-tagging polymorphism on chromosome 8. 
##inversion-tagging polymorphism on chromosome 17.  †proxy for rs6904596 (R2 = 0.98). 
 
Panel A. Genome-Wide Significant Associations 
Subjective Well-Being (SWB, N = 298,420) 
SNPID CHR BP EA EAF Beta SE R2 p-value  N Quasi-Repl 
rs3756290 5 130,951,750 A 0.24 -0.0177 0.0031 0.011% 9.6×10-9 286,851 
rs2075677 20 47,701,024 A 0.76 0.0175 0.0031 0.011% 1.5×10-8 288,454 DS** 
rs4958581 5 152,187,729 T 0.66 0.0153 0.0027 0.011% 2.3×10-8 294,043 DS*** 
Neuroticism (N = 170,908) 
SNPID CHR BP EA EAF Beta SE R2 p-value  N Quasi-Repl 
rs2572431#  8 11,105,077 T 0.41 0.0283 0.0035 0.039% 4.2×10-16 170,908 SWB* 
rs193236081##  17 44,142,332 T 0.77 -0.0284 0.0045 0.028% 6.3×10-11 151,297 
rs10960103 9 11,699,270 C 0.77 0.0264 0.0038 0.024% 2.1×10-10 165,380 ܦଶଷ௔௡ௗெ௘∗  
rs4938021 11 113,364,803 T 0.34 0.0233 0.0037 0.024% 4.0×10-10 159,900 ܦଶଷ௔௡ௗெ௘∗∗∗ , SWB* 
rs139237746 11 10,253,183 T 0.51 -0.0204 0.0034 0.021% 2.6×10-9 170,908 
rs1557341 18 35,127,427 A 0.34 0.0213 0.0036 0.021% 5.6×10-9 165,579 ܦଶଷ௔௡ௗெ௘∗∗  
rs12938775 17 2,574,821 A 0.47 -0.0202 0.0035 0.020% 8.5×10-9 163,283 SWB* 
rs12961969 18 35,364,098 A 0.2 0.0250 0.0045 0.020% 2.2×10-8 156,758 
rs35688236 3 34,582,993 A 0.69 0.0213 0.0037 0.019% 2.4×10-8 161,636 
rs2150462 9 23,316,330 C 0.26 -0.0217 0.0038 0.018% 2.7×10-8 170,907 
rs12903563 15 78,033,735 T 0.50 0.0198 0.0036 0.020% 2.9×10-8 157,562 ܦଶଷ௔௡ௗெ௘∗ ,SWB* 
Depressive Symptoms (DS, N = 180,866) 
SNPID CHR BP EA EAF Beta SE R2 p-value  N Quasi-Repl/Repl 
rs7973260 12 118,375,486 A 0.19 0.0306 0.0051 0.029% 1.8×10-9 124,498 ܦଶଷ௔௡ௗெ௘∗  
rs62100776 18 50,754,633 A 0.56 -0.0252 0.0044 0.031% 8.5×10-9 105,739 ܦଶଷ௔௡ௗெ௘∗∗ ,SWB* 
Panel B.  SNPs Identified via Proxy-Phenotype Analyses of SWB Loci with p-value<10-4 
Depressive Symptoms in Non-Overlapping Cohorts 
SNPID CHR BP EA EAF BetaDS SEDS R2 pDS Bonferroni NDS 
rs4346787† 6 27,491,299 A 0.113 -0.023 0.0059 0.011% 9.8×10
-5 0.0160 142,265 
rs4481363 5 164,483,794 A 0.524 0.014 0.0038 0.009% 3.1×10
-4 0.0499 142,265 
Neuroticism in Non-Overlapping Cohorts 
SNPID CHR BP EA EAF Betaneuro SEneuro R2 pneuro Bonferroni Nneuro 
rs10838738 11 47,663,049 A 0.49 0.0178 0.0039 0.016% 5.0×10-6 0.0009 131,864 
rs10774909 12 117,674,129 C 0.52 -0.0150 0.0039 0.011% 1.2×10-4 0.0203 131,235 
rs6904596 6 27,491,299 A 0.09 -0.0264 0.0072 0.012% 2.5×10-4 0.0423 116,335 
rs4481363 5 164,474,719 A 0.49 0.0151 0.0040 0.011% 1.9×10-4 0.0316 122,592 
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ONLINE METHODS 
This article is accompanied by a Supplementary Note with further details. 
GWAS of subjective well-being. Genome-wide association analyses were 
performed at the cohort level according to a pre-specified analysis plan. Genotyping 
was performed using a range of common, commercially available genotyping arrays. 
The analysis plan instructed cohorts to upload results imputed using the HapMap2 
CEU (r22.b36) reference sample37. We meta-analyzed summary association 
statistics from 59 contributing cohorts with a combined sample size of 298,420 
individuals. Before meta-analysis, a uniform set of quality-control (QC) procedures 
were applied to the cohort-level summary statistics, including but not limited to the 
EasyQC38 protocol. All analyses were restricted to European-ancestry individuals. 
We performed a sample-size-weighted meta-analysis of the cohort-level summary 
statistics. To adjust standard errors for non-independence, we inflated them using 
the square root of the estimated intercept from a LD Score regression10. We also 
performed secondary, separate meta-analyses of positive affect (N = 180,281) and 
life satisfaction (N = 166,205) and a post hoc genome-wide analysis of subjective 
well-being in cohorts with 1000G-imputed data (N = 229,883); see Supplementary 
Figures 4-6. 
Detailed cohort descriptions, information about cohort-level genotyping and 
imputation procedures, cohort-level measures, and quality-control filters are shown 
in Supplementary Tables 2-6. Supplementary Table 7 reports association results 
from the following four meta-analyses: the primary subjective well-being analysis, the 
life satisfaction analysis, the positive affect analysis, and the post hoc subjective 
well-being analysis. For each phenotype, we provide association results for the set of 
approximately independent SNPs that attained a p-value smaller than 10-5. We 
identify these SNP using the same clumping algorithm as for the lead SNPs, but with 
the p-value threshold set at 10-5 instead of genome-wide significance. 
GWAS of depressive symptoms and neuroticism. Our auxiliary genome-wide 
association studies of DS and neuroticism were conducted in 1000G-imputed data, 
combining new genome-wide association analyses with publicly available summary 
statistics from previously published studies. We applied a similar QC protocol to that 
used in our primary subjective well-being analysis. In the DS meta-analysis (N = 
180,866), we weighted the UKB analysis by sample size and the two case-control 
studies by effective sample size. In the neuroticism meta-analysis, we performed a 
sample-size-weighted fixed-effects meta-analysis of the UKB data and the publicly 
available summary statistics from a previous GWAS of neuroticism.  
Detailed cohort descriptions, information about cohort-level genotyping and 
imputation procedures and quality-control filters are provided in Supplementary 
Tables 8-12. See Supplementary Figure 7 for quantile-quantile plots of the 
neuroticism and DS meta-analysis results. Association results for the set of 
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approximately independent set of SNPs that attained a p-value smaller than 10-5 are 
supplied in Supplementary Table 25. 
Population stratification. To quantify the fraction of the observed inflation of the 
mean test statistic that is due to bias, we used LD Score regression10. The estimated 
LD Score regression intercepts were all close to 1, suggesting no appreciable 
inflation of the test statistics attributable to population stratification in any of our 
subjective well-being, depressive symptoms, or neuroticism meta-analyses 
(Supplementary Fig. 8). For all three phenotypes, our estimates suggest that less 
than 2% of the observed inflation of the mean test statistic was accounted for by 
bias. 
In our primary GWAS of subjective well-being, we also used two family-based 
analyses to test for and quantify stratification biases. These analyses used within-
family (WF) estimates, the coefficients from regressing the difference in phenotype 
across siblings on the difference in siblings’ genotype (and controls). These WF 
estimates are not biased by population stratification because siblings share their 
ancestry entirely, and therefore differences in siblings’ genotypes cannot be due to 
the siblings being from different population groups. We meta-analyzed association 
statistics from WF analyses conducted in four cohorts. 
In the first analysis, we estimated the fraction of SNPs for which the signs of the WF 
estimates were concordant with the signs of the estimates obtained from a GWAS 
identical to our primary subjective well-being GWAS except with the four family 
cohorts excluded. For the 112,884 approximately independent SNPs considered, we 
found a sign concordance of 50.83%, which is significantly greater than 50% (p = 
1.04 × 10-8). Under the null hypothesis of no population stratification, the observed 
sign concordance matches the expected rate after winner’s curse adjustment nearly 
perfectly, 50.83% (Supplementary Fig 9). 
The second analysis utilized the WF regression coefficient estimates (i.e., not only 
their signs) to estimate the amount of stratification bias. For each SNP ݆, let ߚመ௝ 
denote the GWAS estimate, and let ߚመௐி,௝ denote the WF estimate. Under the 
assumption that the causal effect of each SNP is the same within families as in the 
population, we can decompose the estimates as: 
ߚመ௝ ൌ ߚ௝ ൅ ݏ௝ ൅ ௝ܷ	
ߚመௐி,௝ ൌ ߚ௝ ൅ ௝ܸ, 
where ߚ௝ is the true underlying GWAS parameter for SNP ݆, ݏ௝ is the bias due to 
stratification (defined to be orthogonal to ߚ௝ and ௝ܷ), and ௝ܷ and ௝ܸ are the sampling 
variances of the estimates with Eሺ ௝ܷሻ ൌ Eሺ ௝ܸሻ ൌ 0. Whenever ݏ௝ ്	0, the GWAS 
estimate of ߚመ௝	is biased away from the population parameter ߚ௝. The proportion of 
variance in the GWAS coefficients accounted for by true genetic signals can be 
written as: 
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Varሺߚ௝ሻ
Var൫ߚ௝൯ ൅ Varሺݏ௝ሻ. 
In Supplementary Note, we show that with estimates ߚመ௝ and ߚመௐி,௝ (and their 
standard errors) from independent samples, it is possible to consistently estimate the 
above ratio. The 95% confidence interval for the ratio implies that between 72% and 
100% of the signal in the GWAS estimates is a result of true genetic effects on 
subjective well-being rather than stratification. 
Analyses of inversion polymorphisms. Two genome-wide significant SNPs for the 
neuroticism analysis are located within well-known inversion polymorphisms, on 
chromosomes 8 and 17. Using the genotypic data available for UKB participants, we 
called the inversion genotypes for UKB participants using a PCA-mixture method. 
For both inversions, the method clearly distinguishes 3 clusters of genotypes, 
corresponding to inversion genotypes (Supplementary Fig. 10). We validated the 
PCA-mixture procedure using existing methods designed to call inversion 
genotypes39 (Supplementary Table 26). 
For both inversions, we established that the inversion-tagging SNPs were always 
located in close proximity of the inversion region (Fig. 3b and Supplementary Figs. 
10-11). Supplementary Tables 27-28 list the twenty variants that most strongly 
correlate with the PCs that capture the inversion polymorphisms on chromosome 8 
and 17, respectively. In additional analyses, we confirmed that the inversion is 
associated with neuroticism and subjective well-being in independent cohorts 
(Supplementary Tables 29-30 and Supplementary Fig. 12-13). 
Proxy-phenotype analyses. In these analyses, we used a two-stage approach that 
has been successfully applied in other contexts6. In the first stage, we conducted a 
meta-analysis of our first-stage “proxy phenotype” and used our clumping procedure 
to identify the set of approximately independent SNPs at the p-value threshold of 10-
4. In the second stage, we tested SNPs identified in stage 1 (or high-LD proxies for 
them) for association with a second-stage phenotype in an independent (non-
overlapping) sample. In our analyses, we used our primary phenotype of subjective 
well-being as the proxy-phenotype. We conducted one analysis with depressive 
symptoms as the second-stage phenotype, and one analysis with neuroticism as the 
second-stage phenotype. In the analyses, we omit cohorts from the first-stage or 
second-stage as needed to ensure that the samples in the two stages are non-
overlapping. Supplementary Table 31 lists the cohort restrictions imposed. These 
cohort restrictions, as well as the p-value threshold of 10-4, were chosen before the 
data were analyzed on the basis of statistical power calculations. 
To test for cross-phenotype enrichment, we used a non-parametric procedure that 
tests whether the lead SNPs are more strongly associated with the second-stage 
phenotype than randomly chosen sets of SNPs with a similar distribution of allele 
frequencies (Supplementary Note). 
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To test the individual lead SNPs for experiment-wide significance, we examined 
whether any of the lead SNPs (or their high-LD proxies) are significantly associated 
with the second-stage phenotype at the Bonferroni-adjusted significance level of 
0.05/Y. 
Genetic correlations. We used bivariate LD Score regression10 to quantify the 
amount of genetic heterogeneity among the phenotypic measures pooled in each of 
our three separate meta-analyses. For subjective well-being, we estimated a 
pairwise correlation of 0.981 (SE = 0.065) between life satisfaction and positive 
affect, 0.897 (SE = 0.017) between “wellbeing” (our measure that combines life 
satisfaction and positive affect) and life satisfaction, and 1.031 (SE = 0.019) between 
positive affect and wellbeing. For depressive symptoms, we estimated a genetic 
correlation of 0.588 (SE = 0.242) between GERA and PGC, 0.972 (SE = 0.216) 
between GERA and UKB, and 0.797 (SE = 0.108) between UKB and PGC. Finally, 
we estimated a genetic correlation of 1.11 (SE = 0.14) between the measures of 
neuroticism in the UKB analyses and the summary statistics from a previously 
published meta-analysis4. 
Bayesian credibility analyses. To evaluate the credibility of our findings, we use a 
standard Bayesian framework19 in which our prior distribution for any SNP’s effect is: 
ߚ~ ൜ܰ൫0, ௝߬ଶ൯ with	probability	ߨ0 otherwise. . 
Here, ߨ is the fraction of non-null SNPs, and ௝߬ଶ is the variance of the non-null SNPs 
for trait j ∈ {subjective well-being, depressive symptoms, neuroticism}. In this 
framework, credibility is defined as the probability that a given SNP is non-null. 
We begin with univariate analyses of the GWAS results that do not incorporate the 
additional information from the quasi-replication analyses of the 16 lead SNPs 
reported in Table 1. We use the three subjective well-being-associated SNPs to 
illustrate our approach, but we use analogous procedures when analyzing 
depressive symptoms and neuroticism. We calculate credibility for each value 
ߨ ∈ ሼ0.01,0.02,… ,0.99ሽ. For each assumed value of ߨ, we estimate ߬ௌௐ஻ଶ  by maximum 
likelihood (Supplementary Note). For each SNP, we use Bayes’ rule to obtain a 
posterior estimate of credibility for each of the assumed values of ߨ. Supplementary 
Figure 14 shows that for all considered values of ߨ and all three SNPs, the posterior 
probability that the SNP is null is below 1%. Similar analyses of the depressive 
symptoms and neuroticism SNPs show that the posterior probability never exceeds 
5%. 
In our joint analyses, we consider two phenotypes with genetic correlation ݎ௚. We 
make the simplifying assumption that the set of null SNPs is the same for both 
phenotypes. The joint distribution of a SNP’s effect on the two phenotypes is then 
given by 
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൤ߚଵߚଶ൨~
ە
۔
ۓܰ ቆቂ00ቃ , ቈ
߬ଵଶ ߬ଵ߬ଶݎ௚
߬ଵ߬ଶݎ௚ ߬ଶଶ ቉ቇ with	probability	ߨ
ቂ00ቃ																																											 otherwise.
 
With coefficient estimates, ߚመଵ and ߚመଶ, obtained from non-overlapping samples, the 
variance-covariance matrix of the estimation error will be diagonal. We denote the 
diagonal entries of this matrix, which represent the variances of the estimation error 
in the two samples, by ߪଵଶ and ߪଶଶ. This gives us the joint prior distribution 
ቈߚመଵߚመଶ቉~
ۖە
۔
ۖۓܰ ቆቂ00ቃ , ቈ
߬ଵଶ ߬ଵ߬ଶݎ௚
߬ଵ߬ଶݎ௚ ߬ଶଶ ቉ ൅ ൤
ߪ12 0
0 σ22൨ቇ											 with	probability	ߨ
ܰ ൬ቂ00ቃ , ൤
ߪ12 0
0 σ22൨൰.																																															 otherwise.
 
To select parameter values for the prior, we use the estimates of ݎ௚ reported in 
Supplementary Table 1, and we estimate the parameters ߨ, ߬ଵଶ, and ߬ଶଶ from GWAS 
summary statistics using a maximum likelihood procedure. For this procedure, we 
make the standard assumption10,40 that the variance of a SNP’s effect size is 
inversely proportional to the variance of its genotype, 2 ൈ MAF ൈ ሺ1 െ MAFሻ.  
The credibility estimates follow from applying Bayes’ Rule to calculate either the 
probability that the SNP is non-null (an event denoted ܥ) given only the first-stage 
estimate, ܲ൫ܥ	|	ߚመଵ൯, or the probability that the SNP is non-null conditional on the 
results of both the first-stage GWAS and the quasi-replication analysis, ܲ൫ܥ	|	ߚመଵ, ߚመଶ൯. 
Credibility estimates for our lead SNPs are in Supplementary Table 14. 
To calculate the expected record of a replication or quasi-replication study, we 
assume that the SNP is non-null for both phenotypes. (This is analogous to a 
standard power calculation for a single phenotype, in which the SNP is assumed to 
be non-null.) Under this assumption, ߚመଵ and ߚመଶ are jointly normally distributed, 
implying that the conditional distribution of ߚመଶ given ߚመଵ is 
൫ߚመଶ	|	ߚመଵ, ܥ൯~ܰ ቈ ߬ଵ߬ଶݎ௚߬ଵଶ ൅ ߪଵଶ ߚ
መଵ,
ሺ߬ଵଶ ൅ ߪଵଶሻሺ߬ଶଶ ൅ ߪଶଶሻ െ ߬ଵଶτଶଶݎ௚ଶ
߬ଵଶ ൅ ߪଵଶ ቉. 
Using this equation, we can calculate the probability that the GWAS estimates will 
have concordant signs across the two phenotypes, or that the GWAS estimate of the 
second-stage phenotype will reach some level of significance. These probabilities 
can be summed over the set of lead SNPs to generate the expected number of 
SNPs meeting the criterion. 
To obtain effect-size estimates for a SNP that are adjusted for the winner’s curse 
(Supplementary Table 32), we use the mean of the posterior distribution of the 
SNP’s effect, conditional on the quasi-replication result and the SNP being non-null. 
We derive the posterior distribution and expected ܴଶ in the Supplementary Note.  
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Lookup of depressive symptoms and neuroticism-associated SNPs in an 
independent depression study. We partnered with the investigators of an ongoing 
large-scale GWAS of major depressive symptoms (N = 368,890) to follow up on the 
associations identified in the depressive symptoms and neuroticism analyses. The 
participants of the study were all European-ancestry customers of 23andMe, a 
personal genomics company, who responded to online survey questions about 
mental health. We did not request results for the SNPs identified in the subjective 
well-being or proxy-phenotype analyses, since these were both conducted in 
samples that overlap with 23andMe’s depression sample. For details on association 
models, quality-control filters, and the ascertainment of depression status, we refer 
to the companion study21. The p-values we report are based on standard errors that 
have been inflated by the square by the intercept from an LD score regression10.  
Polygenic prediction. To evaluate the predictive power of a polygenic score derived 
from the subjective well-being meta-analysis results, we used two independent hold-
out cohorts: the Health and Retirement Study (HRS41) and the Netherlands Twin 
Register (NTR42,43). To generate the weights for the polygenic score, we performed 
meta-analyses of the pooled subjective well-being phenotype excluding each of the 
holdout cohorts, applying a minimum-sample-size filter of 100,000 individuals 
(Supplementary Note). The results from these analyses are reported in 
Supplementary Table 33 and depicted in Supplementary Figure 15. 
Biological annotation. For the biological annotation of the 20 SNPs in Table 1, we 
generated a list of LD partners for each of the original SNPs. A SNP was considered 
an LD partner for the original SNP if (i) its pairwise LD with the original SNP 
exceeded R2 = 0.6 and (ii) it was located within 250kb of the original SNP. We also 
generated a list of genes residing within loci tagged by our lead SNPs 
(Supplementary Table 34). 
We used the NHGRI GWAS catalog44 to determine which of our 20 SNPs (and their 
LD partners) were in LD with SNPs for which genome-wide significant associations 
have been previously reported. Since the GWAS catalog does not always include the 
most recent GWAS results available, we included additional recent GWAS studies. 
We used the tool HaploReg45 to identify nonsynonymous variants in LD with any of 
the 20 SNPs or their LD partners. 
We examined whether the 20 polymorphisms in Table 1 were associated with gene 
expression levels (Supplementary Table 24 and Supplementary Note). The cis-
eQTL associations were performed in 4,896 peripheral-blood gene expression and 
genome-wide SNP samples from two Dutch cohorts measured on the Affymetrix 
U219 platform42,43,46. We also performed eQTL lookups of our 20 SNPs in the 
Genotype-Tissue Expression Portal47,48. We restricted the search to the following 
trait-relevant tissues: hippocampus, hypothalamus, anterior cingulate cortex (BA24), 
putamen (basal ganglia), frontal cortex (BA9), nucleus accumbens (basal ganglia), 
caudate (basal ganglia), cortex, cerebellar hemisphere, cerebellum, tibial nerve, 
thyroid, adrenal gland, and pituitary. 
29 
  
Finally, using a gene co-expression database49, we explored the predicted functions 
of genes co-locating with the 20 SNPs in Table 1 (Supplementary Table 35).  
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